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The use of propensity scores to control for pretreatment imbalances on observed variables in non-randomized
or observational studies examining the causal effects of treatments or interventions has become widespread over
the past decade. For settings with two conditions of interest such as a treatment and a control, inverse probability
of treatment weighted estimation with propensity scores estimated via boosted models has been shown in simu-
lation studies to yield causal effect estimates with desirable properties. There are tools (e.g., the twang package
in R) and guidance for implementing this method with two treatments. However, there is not such guidance for
analyses of three or more treatments. The goals of this paper are twofold: (1) to provide step-by-step guidance
for researchers who want to implement propensity score weighting for multiple treatments and (2) to propose
the use of generalized boosted models (GBM) for estimation of the necessary propensity score weights. We define
the causal quantities that may be of interest to studies of multiple treatments and derive weighted estimators
of those quantities. We present a detailed plan for using GBM to estimate propensity scores and using those
scores to estimate weights and causal effects. We also provide tools for assessing balance and overlap of pre-
treatment variables among treatment groups in the context of multiple treatments. A case study examining the
effects of three treatment programs for adolescent substance abuse demonstrates the methods. Copyright © 2013
John Wiley & Sons, Ltd.
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1. Introduction
The use of propensity scores to control for pretreatment imbalances on observed variables in non-
randomized or observational studies examining the causal effects of treatments or interventions has
become widespread over the past decade. Authors have used propensity scores to match [1, 2], strat-
ify (subclassify) [3, 4], or weight [5, 6] the samples from the treatment and control groups so that the
distributions (or features of the distributions such as the means) of observed pretreatment characteristics
are similar across the treatment and control groups, thereby reducing or eliminating confounding.
Propensity score techniques are advantageous compared with regression-based, covariate-adjustment
techniques – which correct for imbalances between groups on pretreatment covariates by controlling for
them in regression models for the outcomes – for at least five reasons. First, by summarizing all pre-
treatment variables to a single score, propensity scores are an important dimension reduction tool for
evaluating treatment effects. This characteristic of propensity scores is particularly advantageous over
standard adjustment methods when there exists a potentially large number of pretreatment covariates [3].
Second, propensity score methods derive from a formal model for causal inference, the potential
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outcomes framework, so that causal questions can be well defined and explicitly specified and not con-
flated with the modeling approach as they are with traditional regression approaches. Third, propensity
score methods do not require modeling the mean for the outcome. This can help avoid bias from misspec-
ification of that model [7]. Fourth, propensity score methods avoid extrapolating beyond the observed
data unlike parametric regression modeling for outcomes, which extrapolate whenever the treatment
and control groups are disparate on pretreatment variables [1]. Lastly, propensity score adjustments can
be implemented using only the pretreatment covariates and treatment assignments of study participants
without any use of the outcomes. This feature of propensity score adjustments is valuable because it
eliminates the potential for the choice of model specification for pretreatment variables to be influenced
by its impact on the estimated treatment effect [8].
Most studies that use propensity scores to control for imbalances compare just two treatment groups of
interest (e.g., treatment and control). Nonetheless, a number of papers have shown that propensity score
methods can be extended to the multiple treatment case with three or more conditions of interest (e.g.,
treatment A, treatment B, and control; [9–11]). Theoretical work of Imbens [9] and Imai and van Dyk
[10] developed the causal models and justification for the use of propensity scores to remove bias in cases
with multiple treatment conditions, whereas the work of Robins and colleagues [12] developed the use of
marginal structural models and inverse probability of treatment weighting (IPTW) for modeling causal
effects from multiple treatments. Other authors have provided more specific guidance on implementing
the approaches from Imbens [9] and Imai and van Dyk [10] in practice. For example, Lechner [13] pro-
vided a step-by-step matching protocol for multiple treatments, which has been utilized numerous times
in the economics literature. A citation search found 76 papers that cited Lechner’s paper, most involving
economic evaluations. Zanutto et al. [14] described how to use stratification (subclassification) on the
propensity score in the multiple treatment case, and most recently, Spreeuwenberg et al. [15] presented
a tutorial for using the multinomial propensity scores as controls in the outcome regression model.
Despite these developments on the use of propensity score matching and stratification for more than
two treatments, practical guidance on the use of propensity score weighting when examining multiple
treatment conditions has received very limited attention. In particular, there is very limited guidance on
how to estimate the propensity scores or the subsequent weights. Moreover, the existing applications
have generally relied on parametric estimation of the propensity score via the multinomial, nested, or
ordinal logistic regression model for multiple treatments [12–16]. Spreeuwenberg et al. [15] provided
a step-by-step guide to causal modeling with multiple treatments that suggests multinomial logistic or
probit models or ordinal logistic models be used to estimate the propensity scores and gives guidance
on when one model may be preferable to another. However, the paper offers no guidance on variable
selection or propensity score model tuning within this parametric framework. Zanutto and colleagues
[14] also suggested using ordinal logistic regression to estimate the propensity scores for multiple doses
of treatment. They recommend using the iterative approach of Rosenbaum and Rubin [3] and offer the
necessary modifications to apply the approach to multiple treatments.
Recent studies of propensity score estimation in the binary case of two treatments show that, in terms
of bias reduction and mean squared error (MSE), machine learning methods outperform simple logistic
regression models with iterative variable section [17–19]. By extension, machine learning methods may
also be advantageous in the multiple treatments setting. One such machine learning technique that has
been frequently utilized in the two-treatment case [5, 18, 20] is the generalized boosted model (GBM).
GBM estimates the propensity score for the binary treatment indicator using a flexible estimation method
that can adjust for a large number of pretreatment covariates. GBM estimation involves an iterative pro-
cess with multiple regression trees to capture complex and nonlinear relationships between treatment
assignment and the pretreatment covariates without over-fitting the data [5,21–24]. It works with contin-
uous and discrete pretreatment variables and is invariant to monotonic transformations of them. Further,
one of the most useful features of GBM for estimating the propensity score is that its iterative estimation
procedure can be tuned to find the propensity score model leading to the best balance between treated
and control groups, where balance refers to the similarity between different groups on their propensity
score weighted distributions of pretreatment covariates.
In light of the potential advantages of boosting in the case of three or more treatment conditions,
this paper provides researchers with a tutorial on implementing propensity score weighting using GBM
when examining multiple treatments. Building on Frölich [11], we begin by describing a variety of causal
effect estimands of potential interest when examining more than two treatment conditions (Section 2).
Then, in Section 3, we describe how to estimate the multiple treatment propensity scores using GBMs,
and we introduce useful diagnostic criteria for assessing balance. In Section 4, we use data from a large,
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observational study of adolescent substance users to illustrate GBM-based propensity score estimation
and evaluation of diagnostic criteria for assessing balance in the context of an outcomes analysis of the
relative effectiveness of three different outpatient substance abuse programs for adolescents.
2. Causal effects with multiple treatments
Causal effect estimation begins with an explicit determination of the causal effect ‘estimands’ that
formalize the scientific quantities of interest. The causal effect estimands then become the target of
estimation procedures. Multiple treatments allow for a variety of causal estimands. Not all estimands
will be of interest for every study; the analyst must choose the estimands of interest depending on the
scientific context. Hence, we begin our tutorial with the development of a causal model and a review of
the possible causal estimands for multiple treatments as these must be the foundation of causal analysis.
We introduce the causal estimands for multiple treatments in the context of a case study on adolescent
treatment effects. The Substance Abuse Mental Health Services Administration’s Center for Substance
Abuse Treatment (SAMHSA CSAT) collected data on adolescents receiving substance abuse treatment
services from a variety of different outpatient community-based treatment settings including (i) tradi-
tional programs (community), (ii) programs implementing the evidence-based motivational enhancement
therapy plus cognitive behavior therapy (MET/CBT-5) treatment protocol, and (iii) programs embed-
ded in strengthened communities that link various systems involved in the identification, referral, and
treatment of alcohol and substance abusing youth (Strengthening Communities for Youth (SCY)). One
question of interest is the relative effects of these three alternative approaches for the treatment of sub-
stance use on outcomes at 12 months post-intake. For clarity in our presentation, we will specify causal
effects in terms of these three treatment approaches (community, MET/CBT-5, and SCY). However, our
methodology is not restricted to studies with three treatments; it extends naturally to any number of
treatments given sufficient data.
Let M denote the number of treatments being studied with M D 3 in our case study. Following the
potential outcomes approach for causal inference [25, 26], every youth in the population has a poten-
tial outcome that will result if he or she receives services from each of the three alternative treatment
programs. For an individual, we denote these potential outcomes as Y Œt  for t D 1; 2; 3, where t D 1
denotes the individual’s potential outcome had he or she received the community program, t D 2 the
MET/CBT-5 program, and t D 3 the SCY program. When comparing alternative treatments, the causal
effect of interest for an individual is defined as the difference among the potential outcomes for the same
individual. Thus, possible causal effects of interest might be the relative effectiveness of all possible
pairs of treatments: community versus MET/CBT-5; community versus SCY; and MET/CBT-5 versus
SCY. For an individual, we denote these pairwise effects by DŒt 0; t 00 D Y Œt 0  Y Œt 00 for all t 0 ¤ t 00. In
general, there exist M.M  1/=2 individual pairwise effects.
Causal effects for individuals generally cannot be estimated because of the fundamental problem of
causal inference: We cannot observe an individual under each of the multiple treatments being compared
[26]. Instead, we only observe what happens to an individual under the treatment condition they actu-
ally received. The causal effects we consider involve summary statistics of the individual effects across
populations (or subpopulations) of interest. We consider two such summaries in this paper:
1. Average treatment effect (ATE): The ATE of treatment t 0 relative to treatment t 00 is the com-
parison of mean outcomes had the entire population been observed under one treatment, t 0,
versus had the entire population been observed under another treatment, t 00 [27]. An example
of an ATE from our case study is the mean outcome had all youth in our study been treated
in the community programs compared with the mean outcome had all youth in the study been
treated at the MET/CBT-5 programs. More formally, the ATE for comparing treatment t 0 and
t 00 equals E.DŒt 0; t 00/ = E.Y Œt 0  Y Œt 00/ = E.Y Œt 0/  E.Y Œt 00/, where expectation is over the
entire population. If we define t as the mean outcome for the entire population when treated
with treatment t , that is, t D E.Y Œt /, then the ATE of treatment t 0 relative to t 00 is t 0  t 00 .
In our case study, with three treatment groups, there exist three ATEs, one for each pairwise
comparison (Table I).
2. Average treatment effect among the treated (ATT): In the multiple treatments setting, the defini-
tion of ATT depends on what is meant by ‘the treated’. This language, which is borrowed from the
treatment versus control literature, requires more careful explanation when extended to the multiple
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Table I. Causal estimands for the effects of multiple treatments.
ATT
Effect ATE Community cases MET/CBT-5 cases SCY cases
MET/CBT-5 vs. community 2  1 1;2  1;1 2;2  2;1 *
SCY vs. community 3  1 1;3  1;1 * 3;3  3;1
SCY vs. MET/CBT-5 3  2 * 2;3  2;2 3;3  3;2
The estimands for cells denoted by * theoretically exist but have limited utility in applications, so we do not
consider them in this paper.
treatments settings. The ATT of treatment t 00 among those treated with treatment t 0 (also stated as
the ATT of t 0 relative to t 00) is the comparison, among study participants who were treated with
t 0, of their mean outcome when treated with treatment t 0, as they were, with the mean outcome
they would have had if they had instead been treated with treatment t 00 [27]. For instance, the mean
outcome for youth in the community programs versus the mean outcome for those youth had they
instead been treated at the MET/CBT-5 programs is an ATT that is of interest in our case study.
More formally, if we let t 0;t 00 equal the mean for youth who receive treatment t 0 had they instead
received treatment t 00, that is, t 0;t 00 D E.Y Œt 00 j T D t 0/, then the ATT of treatment t 0 relative to t 00
is t 0;t 0 t 0;t 00 . In our example, with three treatment groups, there exist six ATTs: one for each pair
of treatments, t 0 and t 00, and either the population receiving t 0 or t 00 as the one of interest (Table I).
The t 0;t 00 for t 0 ¤ t 00 are commonly referred to as the ‘counterfactual means’ because they estimate
the mean outcomes for individual for treatments they did not receive, that is, the counterfactuals.
The ATEs and ATTs can differ when the treatment effects DŒt 0; t 00 are not constant across individuals
(i.e., there exists treatment effect heterogeneity). For instance, if standard community outpatient care is
better for some youth, but MET/CBT-5 is better than community care for others, then the ATE, 2 1,
may differ from the ATTs 1;2  1;1 and 2;2  2;1.
The choice of estimand depends on the substantive questions a study hopes to address and the popu-
lation that is the target of the treatment. A study can estimate both ATE and ATT, but one or the other
typically is better suited for any particular situation. The ATEs are more likely to be of interest com-
pared with ATTs if every treatment potentially might be offered to every member of the population. So,
if traditional community-based outpatient programs, programs providing MET/CBT-5, and programs in
strengthened communities would each be appropriate for every youth in the population, then the ATEs
might be of particular interest.
Conversely, if the research question focuses on the effectiveness of one treatment program t 00 (e.g.,
strengthened communities) if it were to replace care for youth who typically received an alternative form
of care, t 0, (e.g., MET/CBT-5 or community), then the ATT, t 0;t 0  t 0;t 00 , would be of interest because
it measures the relative effectiveness of programs t 0 and t 00 on the population receiving program t 0.
Similarly, if the research question is how well is a particular treatment program t 0 matched to the spe-
cific population it targets for its treatment, then the ATTs t 0;t 0  t 0;t 00 or t 0;t 0  t 0;t 000 are likely to be
of interest because they quantify the effects of treatment t 0 relative to the alternatives on the population
targeted by that program. For example, MET/CBT-5 was developed for marijuana users and has less evi-
dence of efficacy among youth who use other drugs such as cocaine or opiates. In this case, estimating
the ATE of MET/CBT-5 for a population that includes many youth who do not use marijuana and/or
have serious criminal problems might not be of interest, but ATTs would be.
The advantage of ATT is that each treatment program is evaluated only on cases it treats. This is
important because youths and treatments may be aligned so that youths assigned to a treatment are the
subset of the population who may fare the best with this treatment. For instance, youth with marijuana
problems are assigned to MET/CBT-5, which has been shown to be more effective with these youth
than others. Disadvantages of ATTs are that they do not support inferences about the relative effects
of programs if they are expanded from their base clientele and they cannot be used to determine if
changing which youth are treated by different types of programs would improve outcomes overall. For
example, the youth in communities that chose to participate in the community strengthening programs
(SCY) might not be the most responsive to this approach to treatment; we might find treatment within a
strengthened community is more effective on the entire population than on the population served by this
program in our study. We could not learn this using ATT, but we could using ATE.
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3. Method for estimating multiple treatment effects using propensity score weights
In Section 2, we presented different types of causal estimands that may be of interest when faced with
more than two treatment groups. After determining which estimand is best suited to answer each of
a study’s research questions, analysts need to obtain accurate estimates of these quantities. This sec-
tion first describes the general framework of using weighting to estimate pairwise ATEs or ATTs
and then provides details how to use GBM to calculate the weights to be plugged into the estimators
developed here.
3.1. Notation and assumptions
To allow for a precise presentation of estimators of ATE or ATT, we need additional notation for the
observed data. For the i D 1; : : : ; n individuals in the observed data, let Ti denote the observed treat-
ment status for the i th individual; that is, Ti D t if individual i was observed under treatment t , where
t 2 f1; : : : ;M g and M is the total possible number of treatments as noted earlier. Let Yi denote the
observed (rather than a potential) outcome for individual i . Each individual has M potential outcomes,
but only the one corresponding to the observed treatment (Ti ) is observed. That is, if for a given unit
i , Ti D t , then Yi D Yi Œt .‡ Let Xi denote the vector of K observed pretreatment covariates. In our
example, Xi includes demographics (race, age, and gender), as well as substance use, criminal activities,
and emotional functioning among other variables at baseline and K D 23 (see Section 5.1.2 for details).
As discussed in Section 1, estimating the effects in Table I is complicated by the fundamental problem
of causal inference and the need to compare different youth receiving different treatments rather than the
same youth receiving multiple treatments to estimate the causal estimands.
Difficulties arise because of possible confounding variables, which are informally defined as pre-
treatment variables directly influencing both observed outcomes Yi and treatment Ti . In observational
studies, because the researchers do not control assignment to the multiple treatment conditions, con-
founding variables could differ across the groups receiving different treatments. These differences could
make the estimation of the causal estimands in Table I impossible without assumptions and methods to
remove differences among groups on observed confounding variables. IPTW [12], described later, is one
methodology to reduce confounding due to observed variables. IPTW relies on two key assumptions in
order to produce unbiased (with large samples) estimates of the ATE or ATTs of Table I. The assump-
tions cannot be tested with data, so analysts need to fully understand the implications of the assumptions
and carefully evaluate their plausibility in the context of their observational study. Hence, we begin our
discussion of IPTW by describing the two assumptions and then turn to defining the IPTW estimators.
Condition 1 (Sufficient overlap or positivity)
Let Ti be the random treatment assignment variable defined earlier, then
0 < pr.Ti D t jX/ < 1 for all X and t
The positivity assumption states that each subject has a non-zero probability of receiving each treatment.
It implies that there are no values of pretreatment variables that could occur only among units receiving
one of the treatments. In the case study, positivity requires that there are no patterns of values for our
23 covariates, which preclude youth from receiving one treatment or another. Lack of overlap in the
true (unknown) distribution of observed pretreatment characteristics between groups receiving different
treatments would imply the positivity assumption is violated. Although we cannot prove lack of overlap
with the observed data (due to small sample error), if we find sets of covariate values that are clearly
disjoint across the three treatment groups, then this may suggest lack of overlap (and therefore a vio-
lation of the positivity assumption). We discuss our exploration of lack of overlap for the case study
in Section 5.2.
Condition 2 (No unknown or unmeasured confounders assumption or exchangeability)
Let Ti Œt  D I.Ti D t /; then T Œt  ? Y Œt  j X:
‡The observed outcome is well defined as equal to the potential outcome only when the consistency assumption holds so that
the potential outcomes have unique value regardless of how the assignment to a treatment resulted in the observed treatment
or other factors surrounding treatment such as the other youth in treatment or the specific provider [28].
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Imbens [9] showed that condition 2 is sufficient for consistent estimation of t and that it is related to
the ‘strong ignorability’ assumption of [29], which requires that treatment indicators be independent of
the entire vector of potential outcomes. Informally, condition 2 assumes that the set of observed pretreat-
ment covariates, Xi , is sufficiently rich such that it includes all variables directly influencing both Ti and
Yi (i.e., there exist no unmeasured or unknown confounders not included in Xi ). Again, there is no way
to test this assumption with the data because it is an assumption about unobserved variables. Typically,
analysts try to include a broad set of covariates in the analysis of causal effects to reduce the potential
that a confounding variable is omitted inadvertently. Substantive experts may be consulted to identify
variables used in the assignment of treatment and which the literature or their experience suggest also
are related to outcomes and could result in confounding. Variables known or strongly believed only to
be related to treatment assignment should not be used in propensity score models. Controlling for such
variables can reduce the precision of estimates and inflate the bias if there are omitted variables [30]. In
our case study, the survey instrument used to collect pretreatment variables was designed to collect data
useful for treatment assignment and generally known to be related to post-treatment outcomes. Hence,
the observed variables are possible confounders, and we test for their relationship to post-treatment
outcomes within treatment groups to identify variables for modeling.
3.2. Inverse-probability of treatment weighting with multiple treatments
It is well established that the averages of the observed outcomes among people who receive treatment
t 0 can be biased or inconsistent as estimates of t 0 or t 00;t 0 for t 00 ¤ t 0 if there is confounding, that is,
if individuals receiving different treatments are different in terms of their potential outcomes [29]. The
problem is that samples receiving the different treatments typically differ in their distributions of pretreat-
ment variables and, therefore, possibly differ in terms of their observed outcomes in ways that are not
attributable to treatment. Assuming all the variables with pretreatment differences are observed and that
the groups have at least some members with similar covariates, that is, conditions 1 and 2 hold, then we
should in principle be able to reweight a treatment sample to make the distribution of covariates match
that of any of the other treatment groups. Several authors [11, 12, 31] have shown this intuition holds
formally provided the weights equal the reciprocal of the probability that a study participant received the
treatment he or she received. This approach to estimating the population means of potential outcomes
is a form of IPTW. We use IPTW to estimate t for each value of t and use these estimates to obtain
treatment effects. Estimates t 0;t 00 for different pairs of treatments also use weighting, but the weights
are modified because the population of interest is not the entire population.
3.2.1. Pairwise ATEs. When interest is in estimating the pairwise ATEs for a set of M treatments (e.g.,
the three pairwise ATEs of Table I: 2  1, 3  1, and 3  2), we need consistent estimates of
the population means of the potential outcomes for each of the treatments (1, 2, and 3) to obtain
estimates of the desired causal effect. Let pt .X/ denote the propensity score, the probability that an indi-
vidual with pretreatment characteristics X receives treatment t (pt .X/ D pr.T Œt  D 1 j X/). A consistent
estimate of t is given by the weighted mean
bt D
Pn
iD1 Ti Œt Yiwi Œt Pn
iD1 Ti Œt wi Œt 
; (1)
where the weights satisfy
wi Œt  D 1
pt .Xi /
; (2)
provided conditions 1 and 2 hold [11, 32]. We estimate treatment effects of interest using the formu-
las for the estimands in Table I with the unknown population means replaced by their estimates. For
instance, we estimate the ATE of MET/CBT-5 relative to traditional community-based care, 2 1, by
the b2  b1, and similar replacements would be used to estimate the other two ATEs.
3.2.2. Pairwise ATTs. When interest is in estimating the pairwise ATTs for a set of M treatments for
the population receiving one of the treatments t 0 (e.g., the two pairwise ATTs for community cases in
Table I: 1;21;1 and 1;31;1), we need consistent estimates for the mean of the potential outcomes
for youth like those who received the treatment t 0 had they received the other treatment conditions (1;2
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and 1;3 in our example). Under conditions 1 and 2, a consistent estimate of t 0;t 00 will be given by the
weighted mean
bt 0;t 00 D
Pn
iD1 Ti Œt 00Yiwi Œt 0; t 00Pn




0; t 00 D pt 0.Xi /=pt 00.Xi /; (4)
and t 0;t 0 will be consistently estimated using
bt 0;t 0 D
Pn
iD1 Ti Œt 0YiPn
iD1 Ti Œt 0
;
the unweighted mean of observed outcomes from units assigned to treatment t 0 [11].
Here, the appropriate weight for individuals receiving treatment t 00 is the ratio of the probabilities
for receiving t 0 and t 00, pt 0.X/=pt 00.X/. Intuitively, we weight each individual by the reciprocal of their
probability of receiving the treatment they received relative to the probability of receiving the target
treatment. Individuals with covariate values that are much more common in their own treatment group
than in the target group (i.e., pt 00.X/ is very large relative to pt 0.X/ or pt 0.X/=pt 00.X/ is small) have
small weights because they are relatively too common in their sample but not the targeted sample. Indi-
viduals with covariate values that are much more common in the target treatment group than in their own
group (pt 00.X/ is very small relative pt 0.X/ or pt 0.X/=pt 00.X/ is large) have large weights because there
are relatively too few of these types of individuals in their sample, and they are most representative of
the target treatment group.
Again, we estimate the treatment effect of interest using the formulas for the ATT estimands in Table I
with the unknown population means replaced by their estimates.
We note that estimating pairwise ATEs and ATTs can be implemented easily by fitting weighted
regression models in the survey packages of many commonly used software packages, including SAS,
STATA, and R, and the online supporting information§ for this paper contains examples of code for using
each of these packages to estimate ATE and ATT. The weighted models must include dummy indicators
for M  1 of the treatment groups to obtain estimates of pairwise ATTs and ATEs (also called treatment
contrasts) along with 95% confidence intervals (and corresponding p-values) for assessing statistical
significance. In the next section, we describe multinomial logistic regression for estimating propensity
scores and then focus on how to use one particularly robust method (GBM) for estimating the propensity
scores and subsequent weights for comparing multiple treatment conditions.
4. Estimating propensity scores and assessing balance
4.1. Estimating multiple propensity scores using multinomial logistic regression
Multinomial logistic regression is a very commonly used approach to modeling the relationship between
covariates and outcomes that take on a small number of discrete values, such as assignment to one of
three treatment conditions, and has been proposed for estimating propensity scores with multiple treat-
ments [15, 32]. It models the probability that an outcome (e.g., treatment assignment, Ti ) equals each
of its possible values as a function of a linear combination of the covariates and their products and
cross products:
P.Ti D t jXi / D e
ˇ0t Xi
1 C PM1t 0D1 eˇ0t0 Xi ; t D 1; : : : ;M  1;
P.Ti D M jXi / D 1
1 C PM1t 0D1 eˇ0t0 Xi ;
where ˇt , t D 1; : : : ;M are unknown and estimated from the data. Given estimates for the unknown
parameters, the P.Ti D t jXi / can be generated and plugged into the formulas for estimating ATEs or
§Supporting information may be found in the online version of this article.
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ATTs. Maximum likelihood is the standard approach to estimating the coefficients, and all of the com-
monly used statistical software packages include routines for fitting these models. This is an extension
of logistic regression for binary or dichotomous variables when M D 2.
The challenge for propensity score estimation is choosing the correct set of interactions and poly-
nomial terms among the covariates to capture any nonlinearities in their relationship to treatment
assignment. There is no standard method for model selection in the context of estimating propensity
scores for IPTW for multiple treatments. There is not even a standard method for estimating propen-
sity scores for weighting with two treatments. For example, Foster [16] used multinomial regression to
estimate propensity scores for different doses of treatment but did not describe the use of any model
selection procedure. For two treatments, the most common approach to variable selection is an iterative
approach first suggested in [3] and used in [4], which is similar to the approach used by Zanutto and
colleagues described later [14]. But this approach is tailored to stratification and is not specifically tuned
for weighted estimation.
Zanutto and colleagues [14] presented a method for selecting the form of propensity score model in
the context of multiple treatment for stratification. A similar approach could be used for weighting. The
algorithm for this approach involves six steps:
1. Fit a simple model with only main effects for all the proposed covariates.
2. For T D 1; : : : ;M , find the areas of common support for bˇ0tXi among all treatment groups, retain
observations that are in the area of common support for all T .
3. Test for balance on the covariates.
4. Add to the model polynomial and cross product terms for covariates that do not balance.
5. Fit the new model.
6. Repeat steps 3–5 until all the covariates are balanced.
Step 2 of the algorithm is meant to ensure sufficient overlap among the treatment groups so that
Condition 1 holds. To test for balance in step 3, Zanutto et al. [14] and Spreeuwenberg et al. [15] sug-
gested testing whether treatment assignment, modeled with M1 indicator variables for the M treatment
conditions, is a significant predictor of each covariate controlling for propensity score strata. If the M 1
degree-of-freedom F -test for treatment assignment is significant, then the covariate is not balanced. The
approach is similar to the testing method in [3] for two treatments. In the context of using propensity
scores to create strata for profiling multiple treatment programs, Huang and colleagues [33] used the
same procedure for testing for balance and updating their model.
The significance test needs to be modified for estimating propensity scores for weighting. Rather than
controlling for propensity score strata in the model for each covariate, the data must be weighted. The
test would then entail – for each pretreatment variable – running a one-way analysis of variance on treat-
ment assignment with each observation weighted by its IPTW and using the M  1 degree-of-freedom
F -test for treatment as the test for balance. The F -test would need to account for weighting. Again if
the test rejects the null hypothesis of no group differences, then the groups are not balanced; otherwise,
there is no evidence of imbalance. An advantage of testing is that it checks for balance on all treatments.
However, the significance test could fail to find group differences significant when the covariates are
imbalanced because the test statistic is imprecise because of weighting. For these reasons, we and other
authors do not recommend using significance test to assess balance. Instead, we suggest the statistics
described in Sections 4.2.2 and 4.2.3.
Step 4 is likely to prove challenging in practice. With multiple covariates and a model for each treat-
ment level, there are many possible interaction and polynomial terms to add to the model any time
covariates do not balance. With even a moderate number of variables and treatments, it will be very time
consuming and probably prohibitive for analysts to try all variations of possible polynomial and inter-
actions terms to add to the model. Obtaining good balance will rely on the analyst’s ability to identify
candidate terms to test models.
Beyond the challenges of implementing this algorithm, parametric logistic regression has been shown
in simulation experiments to yield causal effects estimates with high MSE [17–19,31,34] because linear-
ity assumptions of logistic regression can lead to very small probabilities and extremely large weights.
Large errors can result even if the model is correctly specified [31], and logistic regression can be par-
ticularly problematic if the model is misspecified [17–19, 31, 34]. The possibility of extreme weights
also exists in the multiple treatments setting with multinomial regression. GBM can mitigate both these
challenges to using multinomial regression. It has automated variable selection [5] and, in simulations,
has proven to provide more stable weights than parametric models [17, 18].
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4.2. Estimating multiple propensity scores using GBM
We begin with a brief description of GBM and how it has been used in the binary treatment case and
then turn to applying the methods to more than two treatment conditions.
GBM fits a piecewise constant model to predict a dichotomous outcome (e.g., a binary treatment indi-
cator). The model consists of many simple regression trees [35] iteratively combined to create an overall
piecewise constant function. The iterative fitting algorithm begins with a single simple regression tree,
and at each new iteration, another tree is added. The new tree is chosen to provide the best fit to the
residuals of the model from the previous iteration. This chosen tree also provides the greatest increase
to the log likelihood for the data. When combining trees, the predictions from each tree are shrunken
by a scalar less than one to improve the smoothness of the resulting piecewise constant model and the
overall fit. Each iteration increases the likelihood, and with enough iterations, the model is sufficiently
flexible to perfectly fit the data. The actual algorithm typically considers many iterations of adding trees,
which may overfit the data. To avoid this, GBM selects an intermediate iteration (or number of trees) for
the final model so as to minimize an external criterion such as out-of-sample prediction error or – in the
case of propensity score estimation – imbalance on the pretreatment covariates across the ‘treatment’
and ‘control’ groups [5].
4.2.1. Using GBM to obtain propensity score weights for binary treatments. As noted earlier, we can
utilize GBM to estimate propensity score weights in the binary treatment setting. The key is to use GBM
in the iterative fashion described earlier with the optimal iteration (number of trees) for estimating the
propensity scores set to be the one that minimizes a ‘stopping rule’ criterion based on the difference
between the weighted distributions of the pretreatment covariates in the two treatment conditions.
Several authors [5, 17] have found that among a variety of propensity score estimation methods, GBM
used in this fashion provides estimated weights that yield the best balance of the pretreatment variables
and estimated treatment effects with the smallest MSE in the binary treatment case.
In practice, various stopping rules have been utilized to select the optimal iteration of GBM for use
in estimating propensity score weights, including rules based on summary statistics (i.e., maximum or
mean) of absolute standardized bias (SB, also referred to as the absolute standardized mean difference)
or the Kolmogorov–Smirnov (KS) statistic, which compare the means or the distributions of the covari-
ates between treatment groups. The summaries are computed across the pretreatment covariates used in
the GBM.
For each covariate, the standardized bias (absolute standardized mean difference) equals the absolute
value of the difference between the weighted mean for treatment group and the weighted mean for the
control group divided by unweighted standard deviation of the pooled sample for ATE or divided by the
unweighted standard deviation of the treatment group for ATT. For ATE, for covariate k (k D 1; : : : ; K),
SBk D j NXk1  NXk0j=bk;
where NXkt is the weighted mean of the covariate for treatment (t D 1) or control (t D 0) and bk is the
standard deviation of the covariate for the pooled sample. For ATT,
SBk D j NXk1  NXk0j=bk1;
where the weights equal one for members of the treatment group and bk1 is the standard deviation of the
covariate for the treatment group.
Standardized bias in the binary treatment setting has been shown to be advantageous for assessing
balance because it provides analysts with a way to assess the size of the difference between treatment
groups in the distributions of the variables that is consistent across pretreatment covariates. Further,
because the level of imbalance is placed on the same scale for all covariates, it allows rank-ordering
covariates by the amount of imbalance; this allows consumers of the study results to see which observed
covariates are most and least imbalanced. Generally, standardized mean differences of less than 0.20
are considered small, 0.40 are considered moderate, and 0.60 are considered large [36]. Some authors
consider any standardized difference greater than 0.25 as evidence of imbalance and a potential source
of bias, whereas other authors may wish to use more a more conservative cutoff [7,37,38]. In this paper,
we focus on differences larger than 0.20 as problematic, but analysts can choose their own cutoff value
as deemed appropriate for their given setting.
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The KS statistic depends on the weighted empirical distribution functions for the treatment and
control samples. For covariate k, these are defined as EDFtk.x/ D
Pn
iD1 wi Œt Ti Œt I.Xik 6 x/=Pn
iD1 wi Œt Ti Œt , for t D 0 or 1 and I.Xik 6 x/ equal one if Xik 6 x and zero otherwise.
The KS statistic for this covariate is
KSk D sup
x
j EDF1k.x/  EDF0k.x/ j :
For ATT, the weights equal one for members of the treatment group.
The KS is valuable because it compares the entire distribution rather than just the mean. However,
unlike standardized bias, the distribution of the KS statistic depends on the sample size so there can be
no universal objective guideline for what constitutes a large or small value. For modest to large sample
sizes, we tend to consider KS statistics greater than 0.10 as indications of imbalance. The KS statistic
is very useful for comparing among models because even if there are no absolute standards, the relative
sizes of the KS statistics for weights from different model fits can rank the models.
The Toolkit for Weighting and Analysis of Nonequivalent Groups (twang) is an R package that
implements propensity score estimation via GBM using one (or all) of the four different stopping
rules for selecting the optimal GBM iteration described earlier (e.g., mean standardized bias, maximum
standardized bias, mean KS, or maximum KS across the pretreatment covariates).
4.2.2. Using GBM to estimate ATEs of multiple treatments. Given that GBM has proven to be effec-
tive in studies of two treatments, we propose an extension of the method for estimating propensity score
weights when there are more than two treatments. Specifically, when interest lies in estimating the ATEs,
we propose using GBM in the following fashion to obtain weights. First, create dummy indicators for
each of the M treatment programs, denoted Ti Œt  as earlier (e.g., receiving community treatment program
versus not receiving community treatment program). Then, fit separate GBMs to each dummy treatment
indicator and obtain the estimated propensity score for the given treatment in question (e.g., the proba-
bility of receiving the community treatment program). Finally, use the estimated propensity scores from
each of the GBM fits to compute the ATE weights (Equation (2)) needed to estimate treatment effects.
The general intuition behind this approach is for any given treatment, Ti D t , estimating ATE weights
for this treatment group only requires knowing the probability that each case assigned to this group
received that assignment rather than one to any other treatment. The weights do not differentiate among
the alternative treatments. Hence, for each treatment group, estimating the ATE weight is like the binary
treatment case. Because GBM has been established to yield good ATE weights in the binary treat-
ment setting, it should in principle be able to do the same for each of the separate fits for the Ti Œt .
Fitting GBM one treatment at a time should produce, for individuals assigned to that particular treatment
group, propensity scores and corresponding inverse probability of treatment weights, which balance the
pretreatment characteristics between the group and the entire population. Critically, for each treatment
indicator, we propose that the estimated propensity score, pt .Xi /, be computed from the iteration of the
GBM fit, which yields the ‘best balance’ between units with Ti D t (Ti Œt  D 1) and the pooled sample
from all treatments. We use this as the balance criterion because ATEs are average effects across the
entire population. The entire population is the key target group that each treatment group should match
when weighted, as opposed to, say, those with Ti Œt  D 1 versus those with Ti Œt  D 0.
Balance can be defined by any of the stopping rules described earlier (mean standardized bias,
maximum standardized bias, mean KS, or maximum KS). However, the balance metrics are modified
for ATE with multiple treatments. For covariate k (k D 1; : : : ; K) and treatment t (t D 1; : : : ;M ),
PSBtk D j NXkt  NXkpj=bkp (5)
where PSBtk is the ‘population’ standardized bias, NXkt D
Pn
iD1 Ti Œt Xki=bpt .Xi / = PniD1 Ti Œt =bpt .Xi // is the propensity score weighted mean of the covariate, bpt .Xi / is the estimated propensity score
for the treatment obtained from our GBM fits described earlier, and NXkp and bkp denote the unweighted
mean and standard deviation of the covariate for the pooled sample across all treatments. It allows us to
directly assess how similar each treatment group is to the population in terms of covariate means both
before and after weighting. Hence, PSBtk is an appropriate criterion for assessing balance when one
has more than two treatment conditions. An alternative might be to compute standardized bias for every
possible two-group comparison and summarize balance across those standardized biases. We find such
computations to be cumbersome and less direct than standardizing with respect to the entire population
to which we are trying to draw inferences with ATEs.
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A similar modification is used for the KS statistic for assessing balance with multiple treatments. The
populations KS statistics (PKS) equals
PKStk D sup
x
j EDFtk.x/  EDFpk.x/ j (6)
where EDFpk.x/ D
Pn
iD1 I.Xik 6 x/=n, the unweighted empirical distribution function for the pooled
sample across all treatments. Again, the stopping rules use the maximum or the minimum of either
PSBtk or PKStk across the pretreatment covariates to measure the balance of a treatment group relative
to the population and to choose the optimal GBM iteration.
In our case study example, the procedure for estimating ATE weights proceeds as follows. We fit three
separate binary GBMs. The first would estimate bp1.Xi /, the probability that each youth received com-
munity care given his or her pretreatment covariates. The second estimates bp2.Xi /, the probability that
each youth received MET/CBT-5 given his or her pretreatment covariates, and the third estimates bp3.Xi /,
the probability that each youth received an SCY program given his or her pretreatment covariates.
For ATE weights, our method fits M separate models or probability estimates. It is not fitting a multi-
nomial model to the treatment group assignments. Consequently, for a given youth, the sum of thebpt .Xi /, t D 1; : : : ;M , (bp1.Xi /, bp2.Xi /, and bp3.Xi / in our example) may not equal one as would be
the case if we were to jointly estimate these multiple treatment propensity scores as is carried out with
multinomial logistic regression models. The fact that the estimated propensity scores do not sum to one
is not a problem for estimating weighted ATEs, because for each youth, only bpt .Xi /, the probability of
being assigned the treatment he or she received, is used for weighting his or her data. For each treat-
ment, the primary goal is to weight the group that received that treatment to match the entire sample
and yield an estimate of t that is essentially unconfounded by the observed pretreatment covariates so
these estimated means can be used to estimate treatment effects. We can achieve this goal by estimating
the probability that T Œt  D 1 ignoring the probability of assignment to other treatments provided the
estimated probabilities yield weights that balance the group receiving treatment t and the entire sample.
This is particularly important because obtaining weights via GBM has proven to be more successful for
the task of balancing two groups than the parametric logistic model.
It is possible to use GBM to estimate propensity scores for multiple treatments in which the estimated
probabilities satisfy
P
t bpt .Xi / D 1. The estimation procedure uses the following steps: (1) choose one
treatment group as a holdout, say t D M ; (2) for treatment group T D 1, subset the data to youth with
T D 1 or T D M ; (3) use this subsample of treatment groups with T D 1 and M to fit a GBM model to
obtain estimates, Qp1.Xi / of the P.T D 1 j Xi /; (4) calculate the odds ratio ORi1 D Qp1.Xi /=.1 Qp1.Xi /;
(5) repeat steps 2–4 for the remaining treatments other than the holdout to obtain ORit for t D 2 to
M  1; (6) set ORiM D 1; and (7) set bpt .Xi / D ORit= PMjD1 ORij . These probabilities will sum to
one by construction. The choice of using t D M was arbitrary. Any of the treatment groups could be
chosen as the holdout. However, the estimates could be sensitive to the choice of holdout – changing
the holdout could yield different estimated probabilities. Another possible shortcoming to this method
is that the GBM model is fit using the subsample of treatment groups t and M so that the model is not
tuned for balancing group t to the entire population by default. Hence, we would need to test the balance
of the desired samples separately from the automated fitting in routines such as the twang package in
R . We prefer the alternative approach described earlier, even though it does not yield probabilities that
sum to one, because that approach directly uses the powerful nonparametric modeling capabilities of
GBM to obtain weights with good balancing properties and yields only one estimate rather than one for
each possible holdout group.
4.2.3. Using GBM to estimate ATTs of multiple treatments. When estimating the ATTs for a treat-
ment t 0, the goal is to estimate t 0;t 00 by the weighted mean of the outcomes from the group receiving
treatment t 00 weighted to match the group receiving treatment t 0. To achieve this goal requires balance
between the weighted distributions of covariates for the T D t 00 group and the distribution for the T D t 0
group. Following Equation (4), we could set wi D bp00t .Xi /=bp0t .Xi / with the probabilities estimated using
the algorithm for estimating weights for ATE. However, those weights were chosen to assure balance
between the T D t 00 group and the entire sample and the T D t 0 group and the entire sample. The
weights were not chosen to balance the weighted T D t 00 group and the unweighted T D t 0 group.
We have found that tuning the GBM fits specifically for the estimation goal (i.e., tuning for ATE when
estimating ATE or tuning for ATT when estimating for ATT) yields better balance and subsequent treat-
ment effect estimates with smaller MSE. Hence, we do not recommend using ratios of probabilities
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estimated for estimating ATEs to estimate ATT. Rather, when estimating weights for ATTs, our method
is to fit a GBM to the treatment indicator for T D t 0 using only the subsample with T D t 00 and T D t 0
using the standard stopping rules for estimating ATT with a binary treatment. We then assign individuals
in treatment group t 00 the ATT weights that result from this binary fit. We repeat this procedure for all
t 00 ¤ t 0. This approach for estimation with more than two treatments directly takes advantage of the
excellent balancing properties that GBM has been shown to have for estimating ATT weights for two
treatment groups [17–19]. Because our target population is a particular treatment group (here t 0), it is
important to obtain weights that make every other treatment condition look like t 0. To achieve this, we
must find the weights that make the covariate distributions for each other treatment group match the
distributions for the t 0 group. It is not necessary to have all conditions in the same estimation model;
instead, a pointed comparison between t 0 and t 00 for each t 00 is sufficient and should yield ATT weights
with relatively superior balance for each pairwise comparison. Intuitively, estimating ATT only involves
data from two groups so we can repeatedly use the tools for estimation with two groups to obtain the
desired causal estimates.
4.3. Assessing balance with multiple treatments
Although our proposed method for estimating propensity score weights for multiple treatments via GBM
checks the balance of groups when fitting the GBM model for each treatment group, it is also impor-
tant to have useful diagnostic criteria for assessing overall balance across the multiple groups. An overall
summary of balance across groups will be particularly useful for describing the results of the causal anal-
yses in presentations and publications. For both ATE and ATT estimations, we create overall summary
measures of balance by taking the maximum of the balance metrics for each treatment. Hence, we sum-
marize balance with PSBk D maxt PSBtk and PKSk D maxt PKStk for ATE and TSBk D maxt SBtk
and TKSk D maxt KStk for ATT. We can then summarize metrics PSBk , PKSk , TSBk , and TKSk across
covariates using either the maximum or the average by using before and after weighting plots like those
shown in Figures 1–3 in Section 5.
4.4. Doubly robust estimation
Successfully reweighting the sample yields values of all the summary statistics (PSBtk and PKStk or
TSBtk and TKStk), which are small for all covariates. For both sets of standard bias statistics (PSBtk
and TSBtk), we consider values of less than 0.20 to be small, 0.40 to be moderate, and 0.60 to be large
as with traditional standardized bias measures from the binary treatment setting. Covariates that remain
imbalanced after weighting could potentially confound estimated treatment effects and pose a challenge
for which no single solution will be best in all settings.
Sometimes, imbalance indicates separation between the groups on some dimension of the covariates,
and restricting the samples to more comparable subsets can improve balance and yield accurate treat-
ment effect estimates for a well-defined subset of the population. For instance, sometimes, one treatment
group contains only a subset of the individuals found in other groups, and by conducting ATT rather
than ATE analyses, balance may be more easily obtained. To illustrate using our case study, because
MET/CBT-5 was specifically targeted for marijuana users rather than youth using other substances such
as cocaine or opiates, it may be the case that if the community and SCY groups include many youth who
use substances other than marijuana, it may be difficult to weight the MET/CBT-5 sample to match the
entire population. Instead, focusing in on ATT for effects of MET/CBT-5 sample might result in better
balance and unconfounded treatment effects.
When imbalances remain after weighting, another commonly used approach models the outcomes
including the imbalanced covariates in the model. Model parameters including treatment effects are
obtained by fitting a weighted regression. This approach is most advisable when the remaining imbal-
ances are modest because the idea is that when the differences in the groups are modest, the model can
control for them and any errors in the model will tend to be small. Estimating treatment effects through
weighted regression on treatment indicators and covariates is a form of ‘doubly robust’ estimation, which
combines a model for the outcome with weighting to obtain an estimator that yields consistent estimates
of the treatment effect if either the model for the outcome or the propensity score model is correct but
not necessarily both [31]. There are many different estimators that have the doubly robust property, one
of which is weighted linear regression [31], and they can be used even if all the covariates balance to
provide protection against possible errors in the propensity score model. Doubly robust estimation can
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also be more efficient than the simple weighted estimator [39]. Hence, some analysts might always com-
bine weighting and modeling. However, concerns may arise when there are many covariates to include in
the weighted regression model. It is likely that such cases will require variable selection, thereby under-
mining one of the key features of the propensity score approach: separating the modeling to control of
confounding from the estimation of the treatment effect. For this reason, some analysts might prefer
weighting alone.
Some papers have clearly shown that doubly robust estimation yield more accurate treatment effect
estimates [39], but these have not considered multiple covariates with differing relationships with the
outcome. We prefer to use weighted models alone or to control for pretreatment covariates that remain
imbalanced after weighting in the regression model for the outcome(s). We also use doubly robust esti-
mation, but we identify key covariates substantively (e.g., baseline values of the outcomes). Further, we
prefer to control for these covariates in models for the outcome without additional variable selection.
This is akin to the analysis of randomized trial data where a set of pretreatment covariates are speci-
fied in the design of the trial (before data are collected) and adjusted for in the model for the primary
outcomes without additional variable selection.
4.5. Effective sample sizes
In general, weighted treatment effect estimates such as those defined in Equations (1) and (3) can have
greater sampling variance than unweighted means from a sample of equal size. The effective sample size
(ESS) of the weighted treatment group is a conservative way to capture the impact of this increase in
variance on precision and power. Specifically, ESSt D
PN




iD1 Ti Œt w2i for treatment
t where wi D 1=bpt .Xi / if one is estimating ATEs and wi D Wi Œt 0; t 00 if one is estimating ATTs.
The ESSt provides a useful measure of the disparity in the weights for a treatment group’s sample and
the potential loss in precision from weighting. The ratio of the ESSt to the number of observations in a
treatment group sample equals the loss in precision because of weighting, if the outcome is uncorrelated
with the weights [40]. If the outcome is correlated with the weights, then there may be no loss in pre-
cision because of weighting, or the loss may be much smaller than suggested by the ratio of the ESSt
to the sample size [40]. Regardless, very small values of the ESSt relative to the sample size indicate
a great disparity in the weights for the treatment group sample and typically that a small number of
units receive very high weights relative to the majority of the units in the sample. Such a disparity in the
weights could lead to unstable estimates dominated by a few cases and signal weak overlap among the
groups. Furthermore, if two alternative GBM fits yield essentially equal balance but one yields a larger
ESSt than the other, then the fit yielding the larger ESSt is preferred. Hence, ESSt can be very useful
for choosing among alternative models and assessing the overall quality of a model, even if it provides a
possibly conservative picture of the loss in precision because of weighting.
5. Illustrative data example
The approach described earlier for estimating multiple propensity scores using GBM and assessing
balance for different types of causal estimands is implemented in the twang package in R. We now
illustrate our approach for estimating the different causal estimands (pairwise ATEs and ATTs) using
this package and the CSAT’s observational data on three different outpatient treatment approaches:
community-based care, MET/CBT-5, and SCY. We first provide additional details about each treatment
approach and the sample from each program. Then, we describe the observed pretreatment variables
available for removing differences among the groups and the outcome of interest, which measures sub-
stance use frequency. We estimate the three propensity score models and finally estimate all pairwise
ATE and ATT effects.
5.1. Data and measures
5.1.1. Study samples. We collected data for our example under three distinct discretionary grant pro-
grams administered by the SAMHSA’s CSAT. Data from the three programs can be readily merged
because each had a 12-month follow-up and utilized the same survey instrument to measure pretreatment
covariates and outcomes.
The community sample in our analysis comes from the Adolescent Treatment Model (ATM) program,
which was an observational study of 10 ‘exemplary’ community-based care treatment programs funded
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in 1998–1999 to collect detailed survey information on clients at intake and 90-day intervals for 1 year
post-intake to study the relative effectiveness of various models of adolescent substance abuse treat-
ment [41]. Extensive details about the programs can be found in [42]. We only use data from the three
outpatient programs of the ATM for our community sample.
The MET/CBT-5 sample comes from the Effective Adolescent Treatment (EAT) program, which was
designed to disseminate the evidence-supported treatment to community-based treatment programs start-
ing in 2003. The EAT included 37 community-based adolescent substance abuse treatment sites, all of
which delivered MET/CBT-5. Details about the treatment and the EAT sites can be found in [43–45].
The SCY group comes from the same named program (Strengthening Communities for Youth), which
implemented procedures meant to improve community collaboration. Specifically, in 2001–2002, CSAT
initiated its SCY program to fund 12 communities to ‘strengthen their drug and alcohol identification,
referral, and treatment systems for youth’ (SAMHSA/CSAT 2001 GFA No. TI 01-004); see [46] for
more details. The current analysis is restricted to the eight SCY communities that collected data at base-
line and 12 months post-intake using the Global Appraisal of Individual Needs (GAIN; see details in the
following discussion) without extensive modifications and were willing to share their data for studies of
the SCY program.
Providers in each of the three types of programs offer outpatient community-based care but with dif-
ferent practices and under different conditions: The ATM group (community) represents standard prac-
tice, the EAT group (MET/CBT-5) represents practices that are translating evidence-based protocols in
community settings, and the SCY group represents practices within an enhanced community setting with
strengthened ties among its various drug and alcohol identification, referral, and treatment systems. For
all three programs, clients were interviewed using the same biopsychosocial instrument (GAIN [47]) at
intake and for a year thereafter.
5.1.2. Pretreatment measures. All pretreatment measures come from the GAIN. The GAIN has eight
sections assessing background and demographic characteristics (baseline only), substance use, physical
health, risk behaviors, mental health, environment, legal, and educational/vocational problem areas. It
includes over 100 symptom counts, change scores, and service utilization indices, most with Cronbach’s
alphas over 0.85 [47]. A test–retest analysis of key GAIN substance use and substance use problem
indices in a sample of 210 adolescents indicated good reliability over a 90-day interval (r > 0:72 for
each index) [46]. We include a total of K D 23 pretreatment measures (Table III), which have been
shown in previous analyses to explain at least 1% of the variance in frequently used outcomes for eval-
uating substance abuse treatment programs [43]. Missing values on the 23 pretreatment variables were
low (mean D 0:73% and max D 4:85%) and controlled for in our propensity score models, which
include missing value indicators as well as the observed values of each pre-treatment variable (details in
following section).
5.1.3. Outcome. The Substance Frequency Scale is an 8-item scale that assesses the average propor-
tion of alcohol and other drug using days in the past 90 taking into account heavy use and problem
days. Higher scores indicate increased frequency of substance use in terms of days used, days staying
high most of the day, and days causing problems. Inter-item reliability was good (˛ D 0:80) in the
ATM dataset.
5.2. Estimating causal effects
Table II lists the steps we use when estimating the causal effects of multiple treatments using weighting.
The following subsections highlight implementation of each step using the community, MET/CBT-5,
and SCY treatment programs. As noted earlier, t D 1 denotes community, t D 2 denotes MET/CBT-5,
and t D 3 denotes SCY.
Step 1. Estimating propensity scores
When interested in ATE
Suppose we are interested in estimating the pairwise ATEs. In this case with three treatments, there are
three possible ATEs of interest (MET/CBT-5 vs. Community, 2  1; SCY vs. Community, 3  1;
and SCY vs. MET/CBT-5, 3  2). To estimate all three ATEs, the first step of the analysis fits
three binary GBMs, one for each treatment program indicator (community, MET/CBT-5, or SCY). Each
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Table II. Steps in estimating effects of multiple treatments.
1. Estimate propensity scores for each treatment by running mnps() function in twang
2. Assess balance using desired balance metric(s)
3. Assess overlap among treatment samples
4. Estimate the targeted population mean for each treatment
4.1 Set weights equal to the reciprocal of the propensity scores for ATE or
the ratio of treatment to target treatment propensity scores for ATT
4.2 Calculate the weighted mean for each treatment
5. Estimate causal treatment effects
5.1 If all covariates are balanced, use difference in weighted means to estimate treatment effects
5.2 If some covariates remain imbalanced, estimate effects via a doubly robust procedure such as
fitting a weighted regression model that includes unbalance covariates
GBM uses an ATE stopping rule that selects the iteration that yields optimal balance defined by PSBtk
and/or PKStk . We use the mean and maximum standardized bias stopping rules when exploring fits for
this analysis.
When interested in ATT
To illustrate what happens when estimating ATT weights, we begin by assuming that it is of interest
to estimate ATT for youth like those who were in the MET/CBT-5 condition. In this case, there are
two ATTs of potential interest (MET/CBT-5 vs. Community, 2;2  2;1; and MET/CBT-5 vs. SCY
2;2  2;3 for youth like those receiving MET/CBT-5). Therefore, the analysis begins by creating
two subsamples from the overall dataset: One that contains youth in the MET/CBT-5 and community
groups, and the other that contains youth in the MET/CBT-5 and SCY groups. To estimate the weights
for estimating the ATT of MET/CBT-5 relative to community among youth like those who received
MET/CBT-5 (2;2  2;1), we fit a binary GBM propensity score model for the MET/CBT-5 treatment
indicator to the pooled sample with youth from the MET/CBT-5 and community samples. We use an ATT
stopping rule that selects the iteration of GBM, which yields optimal balance defined by TSBtk and/or
TKStk . From this model, we obtain estimates of the probability that each youth in the subsample received
MET/CBT-5 rather than community care. The ATT weights equal one for youth in the MET/CBT-5 sam-
ple, and it equals the ratio of the propensity score to one minus the propensity score (the odds of receiving
MET/CBT-5 rather than community care) for youth in the community sample. These are the same
weights we would use if there were only two treatments. In essence, we are estimating the pairwise treat-
ment effects for multiple treatments by repeatedly using the methods for causal effects for cases with just
two treatments.
We then repeat the GBM estimation procedure of using the sample with youth from the MET/CBT-
5 and SCY groups to estimate the ATT of MET/CBT-5 relatively; SCY for youth like those receiving
MET/CBT-5, 2;2  2;3. Again, we use the binary GBM propensity score model for the MET/CBT-5
treatment to estimate the probability of receiving MET/CBT-5 rather than SCY. The weights are one for
youth in the MET/CBT-5 sample and the odds of receiving MET/CBT-5 rather than SCY for the youth
in the SCY sample.
We use a similar process to estimate ATT for youth like those receiving community care and ATT
for youth like those receiving SCY. For expository purposes, we estimate all the pairwise ATT estimates
using each of the three treatments to define the target population. Applications might usually focus on
only a single target population.
We used the mnps() function in twang to estimate both the ATE and ATT weights for our case
study. The function automates the propensity score and weight estimation process by running the
GBM fitting algorithm for many iterations and selecting the iteration to minimize the user-specified
stopping rule. It also produces weights from the selected model and repeats all the steps for all the
treatment groups.
Step 2. Assess balance using desired balance metric(s)
Using ATE weights
Table III shows for each pretreatment variable the unweighted and ATE weighted means for each treat-
ment program and the unweighted overall population mean and standard deviation. Cells marked with
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Table III. Means for treatment groups (unweighted and ATE weighted) and the population (pooled sample,
unweighted).
Unweighted means Weighted means
MET/ MET/ Population
Pretreatment covariate Comm. CTB-5 SCY Comm. CTB-5 SCY Mean SD
Demographics (race/ethnicity)
Percent non-Hispanic white 0.67* 0.51 0.35* 0.59* 0.48 0.46 0.48 0.50
Percent African American (nonH) 0.14 0.08* 0.32* 0.12 0.14 0.17 0.16 0.37
Percent Hispanic 0.10* 0.24 0.2 0.2 0.22 0.22 0.21 0.41
Percent other 0.09 0.17 0.14 0.1 0.16 0.16 0.15 0.36
Substance use
In recovery 0.20 0.25 0.18 0.19 0.23 0.22 0.23 0.42
Substance frequency scale 0.14 0.11 0.15 0.14 0.12 0.13 0.13 0.14
Subs prob scale (past month) 3.11 2.71 3.36 3.15 2.89 2.95 2.96 3.56
Subs prob scale (past year) 7.93* 6.3 7.09 7.82* 6.55 6.66 6.73 4.39
Subs dep scale (past month) 1.02 0.89 1.2 0.94 0.96 1.02 1.01 1.66
Subs dep scale (past year) 3.10* 2.33 2.69 3.15* 2.44 2.48 2.54 2.29
Days drunk/high (past 90 days) 13.78 11.42 18.44 15.2 13.33 13.87 14.06 23.13
Criminal activities
Internal mental distress scale 7.72 7.82 9.33 8.35 8.13 8.51 8.3 8.71
Problem orientation scale 0.99 0.69 1 1.09 0.76 0.82 0.82 1.59
Emotional problems scale 0.28* 0.21 0.24 0.25 0.22 0.23 0.23 0.19
Behavioral complexity scale 12.26* 9.81 10.89 11.8 10.28 10.26 10.44 7.99
Previous mental health trt 0.45 0.36 0.41 0.42 0.38 0.41 0.39 0.49
Mental health trt scale 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.05
Environmental risk
Social risk scale 13.84 12.31* 13.39 13.89 12.57 12.61 13.46 4.55
Crime environment scale 0.24* 0.05 0.13 0.13 0.07 0.09 0.1 0.23
Environmental risk scale 31.43* 35.47 37.23 33.97 35.79 35.72 35.75 9.41
Living in house/apartment 0.85 0.88 0.82 0.88 0.87 0.86 0.86 0.35
Living in jail/correctional facility 0.11 0.05 0.06 0.06 0.05 0.05 0.06 0.24
Other living situation 0.04 0.06 0.13 0.05 0.08 0.08 0.08 0.27
Training activity scale 0.55* 0.66 0.57* 0.61 0.63 0.62 0.64 0.26
N or ESS (weighted) 444 2459 1351 101.17 2113.64 1025.14 4254
Cells marked with an * denote pretreatment covariates for which PSBtk is greater than 0.20 within a given program.
an asterisk denote pretreatment covariates for which PSBtk is greater than 0.20 within a given program.
Table III also highlights the ESSs for the community, MET/CBT-5, and SCY programs after the ATE
weights were applied.
Community. Before weighting, youth in the community program were very different from the
population; PSB1k was greater than 0.20 for 13 of the 24 pretreatment covariates. Specifically, youth
in the community program had higher mean behavioral complexity, crime violence, emotional prob-
lems, illegal activities, controlled environment, criminal justice system, and substance frequency,
problems, and dependence scales than the population, yet lower mean environmental risk and train-
ing activity scales than the population average. They also had higher mean number of days out of the
past 90 spent in an institutionalized setting, a greater percentage of whites, and a lower percentage of
Hispanics than the population. After weighting, the values of PSB1k were generally attenuated for all
pretreatment covariates and only five values greater than 0.20. Specifically, youth in the community pro-
gram still had higher mean illegal activities and controlled environment scales, a greater percentage of
whites, and lower mean environmental risk scales than the population average after weighting.
As expected, the community sample took a large hit with respect to ESS after weighting (originally
N D 444, whereas ESS after ATE weighting D 101:17). This results from the fact that the distribution
of pretreatment covariates in the community was very different from the overall population.
Copyright © 2013 John Wiley & Sons, Ltd. Statist. Med. 2013, 32 3388–3414
3403
D. F. MCCAFFREY ET AL.
MET/CBT-5. Youth in the MET/CBT-5 program only had two pretreatment covariates with PSB2k
greater than 0.20 prior weighting. Specifically, MET/CBT-5 youth had lower mean social risk scale than
the population average and a lower percentage of African Americans. Weighting removed both these
differences. Also, because the MET/CBT-5 sample was so similar to the overall population, the weights
were not highly differential, and the ESS had only a minor reduction compared with the unweighted
sample: N D 2459 versus the ESS after ATE weighting equal to 2113.64.
SCY. The pretreatment variables of youth in the SCY also were very similar to those of the overall
population prior to weighting. Only the percentage of African Americans and whites and training activ-
ity scale were imbalanced prior to weighting. Weighting removed these differences. As with the MET/
CBT-5, the similarity of the means of pretreatment variables for SCY and overall samples prior to weight-
ing resulted in an ESS that differed very little from the actual sample size: N D 1351 versus the ESS
after ATE weighting equal to 1025.14.
Using ATT weights
Figures 1–3 contain a series of plots for assessing the balance between groups on pretreatment variables
before and after ATT weighting. For each treatment, there are two rows of panels, one for comparing
it with each of the other two treatments. For instance, Figure 1 is ATT when community is the tar-
get population. In this figure, the top row compares the community and MET/CBT-5 samples before
and after the MET/CBT-5 sample is weighted to match the distribution of pretreatment variables in the
community sample. The left panel shows the results using the mean standardized bias stopping rule, and
the right panel shows the results using the maximum standardized bias stopping rule. The bottom row
compares the community and the SCY samples when the SCY sample is weighted to match the com-
munity sample. Each point in a panel represents the SBk or effect size difference between samples for
a pretreatment variable. The left column of points in a panel are the SBk for the unweighted samples,
and the right column of points are the values when the comparison treatment is weighted to match the
community sample. Lines connect the values for the same pretreatment variable before and after weight-
ing. A closed red circle indicates a covariate for which the difference between treatment group means
is statistically significant. An open red circle and red line identify a variable for which the standardized
bias or effect size increases with weighting; a blue line identifies a variable for which balance improves
with weighting. Figures 2 and 3 show analogous results for ATT weights when the ‘treated’ popula-
tion is MET/CBT-5 or SCY, respectively. A corresponding table with the ATT weighted means for each
comparison is available in the Supporting information.
Community. In both rows of Figure 1, the samples are very different prior to weighting with many solid
red dots greater than 0.20. The youth in both the MET/CBT-5 and SCY samples differ from the youth in
the community sample on many pretreatment variables, and this is reflected in the panels of the figure.
After weighting, all of the large differences between the means of the pretreatment variables between
community and weighted MET/CBT-5 samples are greatly reduced, but five remain greater than 0.20.
This holds regardless of the stopping rule used to select the GBM for the propensity scores. The bal-
ance is nearly invariant to the stopping rule. There are also large differences between the community
and SCY samples prior to weighting, although there are fewer of these than for MET/CBT-5. Weighting
again reduces these greatly, but three remain above 0.20.
As expected, when using ATT weights that aim to make youth in the MET/CBT-5 and SCY pro-
grams look like community youth, we see a large reduction in ESS. For both programs, the ESS is
85% lower than the unweighted sample sizes for these two programs (originally N D 2459 and 1351
for MET/CBT-5 and SCY, respectively; ESS after ATT community weighting D 379.96 and 199.17,
respectively).
MET/CBT-5. The top row of Figure 2 compares the MET/CBT-5 and community samples before and
after the community sample is weighted to match the MET/CBT-5 sample. The samples differ sub-
stantially on many variables. The SBk are larger in this comparison than when estimating ATT for the
community sample because the variance of the pretreatment variables is smaller in the MET/CBT-5
sample than in the community sample yielding denominators of the standardized biases that are smaller
for ATT on MET/CBT-5. Weighting nearly removes all the difference: Only two remain greater than
0.20. The great reduction in SBk that results from weighting suggests that a subset of the community
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sample is similar to the MET/CBT-5 sample and, when they are up-weighted relative to the other youth
in the community sample, the two groups are similar in terms of the pretreatment variables. However,
this subsample is small. When weighting community youth to look like MET/CBT-5 youth, we have
a 90% drop in the ESS after weighting: ESS in community is 42.19 after weighting, and the sample
size is 444. As shown in the bottom row of Figure 2, the MET/CBT-5 and SCY samples are fairly sim-
ilar prior to weighting with the largest standardized bias being just greater than 0.4. Weighting makes
the differences very small. Again, all the results are relatively invariant to the stopping rule. The loss
in ESS for the SCY group is about 43% (ESS of 769 for the sample of 1351 youth), which is large
given the relative similarity of the pretreatment variables in the SCY and MET/CBT-5 samples priors
to weighting.
SCY. Figure 3 shows the results for weighting community and MET/CBT-5 samples to match the SCY
sample. As noted previously, the community sample differs from the SCY sample, and this is again
reflected in the large values for some of the SBk in the left-hand side columns of the two panels in the
top row of the figure. Weighting reduces all the large differences, but the three variables with largest
differences prior to weighting, race, illegal activities, and the environmental risk scale have the largest
differences after weighting. The SBk > 0:2 for each of these variables. The SCY sample has fewer white
youth with low environmental risks and high rates of criminal activities than the community sample and
weighting cannot fully correct these differences. Conversely, the MET/CBT-5 sample is similar to the
SCY sample before weighting, and with weighting, the MET/CBT-5 sample matches the SCY sample
very well with no SBk greater than 0.15. There is a very large loss in ESS for the community group























































































































Figure 1. Effect size plots for assessing the balance of pretreatment variables on youth like those receiving
Community care for estimating pairwise ATT effects for Community treatment.
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Figure 2. Effect size plots for assessing the balance of pretreatment variables on youth like those receiving
MET/CBT-5 for estimating pairwise ATT effects for MET/CBT-5.
Step 3. Assessing overlap
As discussed in Section 3.1, weighted treatment group means yield consistent estimates of the popula-
tion means of the potential outcomes t , for t D 1; 2; or 3, provided there is overlap among the groups
such that every youth could have received each treatment and there are no values of the pretreatment
variables that occur only in one of the treatment conditions. It is difficult to visually assess overlap in
high dimensions. Consequently, a common approach to assessing overlap compares the distributions of
the estimated propensity scores across the treatments. We have found that box plots work well for com-
paring the distributions of propensity scores. To test the overlap for ATE, we estimate the propensity
score model for each treatment, community, MET/CBT-5, and SCY, and calculate the propensity scores
for every youth in the sample regardless of the youth’s actual assignment. We then plot the distributions
of estimated propensity scores using a separate box plot for the youth receiving each type of treatment.
For example, we first estimate the propensity score model for community treatment using GBM. We
then evaluate these propensity scores for youth in community, MET/CBT-5, and SCY samples, and plot
the distributions of values for each of the three groups using side-by-side box plots. We repeat these
steps for the other two treatments. Figure 4 presents the three sets of three box plots of the distributions
of propensity scores with scores for community in the top panel, MET/CBT-5 in the center panel, and
SCY in the bottom panel.
There are no specific rules for what constitutes sufficient overlap, but substantial overlap of the box
plots is desirable (i.e., the panels for MET/CBT-5 and SCY), and great separation of the plots (the panel
for community) is typically considered insufficient. However, separation in the propensity score box
plots does not necessarily imply that weighting cannot balance the pretreatment variables, and we have
even found examples where tuning the GBM model to achieve greater balance in the covariates resulted
greater separation of the propensity score box plots.
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Figure 3. Effect size plots for assessing the balance of pretreatment variables on youth like those receiving SCY
for estimating pairwise ATT effects for SCY.
Generally, we use a combination of the overlap plot and the balance table to assess whether the groups
are sufficiently similar to support causal estimation of the treatment estimands. The lack of overlap and
poor balance suggests that the groups may be sufficiently distinct so as not to support causal estimation.
For example, the overlap between the community and other groups is poor (see the top panel of Figure 4)
and, as discussed previously in step 2, imbalance between the community group and the overall popula-
tion remains on several variables including race and measures of substance use problems and criminal
activity. White youth with high rates of criminal activity and substance use problems and symptoms of
dependence the year before treatment intake appear in the community sample but not in the other sam-
ples. For these youths, we might not be able to use the other samples to estimate their counterfactual
outcomes following MET/CBT-5 or SCY instead of community treatment. We might need to consider
focusing only on ATT for the other groups or subsetting the population in other ways. As the figures
show, we have good overlap when focusing on MET/CBT-5 or SCY. For the purposes of the tutorial, we
will continue with the estimation of the pairwise ATE and ATT effects, but we need to be cautious in our
interpretation of the ATE estimates.
Steps 4 and 5. Estimating means and causal treatment effects
This section combines steps 4 and 5 in Table II to illustrate how one would estimate ATE and ATT
causal estimands.
Pairwise ATEs
The estimate of the population mean had all youth received community care (1) equals the weighted
mean of youth in the community care sample where the weight for each youth is the reciprocal of the
estimated propensity for receiving community care. We call this estimate b1. Only the outcomes of youth
Copyright © 2013 John Wiley & Sons, Ltd. Statist. Med. 2013, 32 3388–3414
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SCY Propensity Scores by Tx Group
Figure 4. Overlap assessment. Each panel presents box plots by treatment group of the estimated propensity
scores for one of the treatments, pr.T Œt  D 1 j X/ for ever youth in the sample. The top panel presents Community
(t D 1), the middle panel presents MET/CBT-5 (t D 2), and the bottom panel presents SCY (t D 3).
in the community sample are used to estimate this mean because only these youth received community
care. Their weights depend only on their propensity scores for receiving community care. Similarly,
the estimate of the population mean had all youth received MET/CBT-5 equals the weighted mean of
youth in the MET/CBT-5 sample where the weight for each youth equals the reciprocal of the estimated
propensity scores for receiving MET/CBT-5, and the estimate of the population mean had all youth
received SCY equals the weighted mean of youth in the SCY sample where the weight for each youth
equals the reciprocal of the estimated propensity score for receiving SCY. We call these estimates b2
and b3, respectively. We estimate the pairwise ATE by differences of the estimated population means:
the average treatment effect of community care relative to MET/CBT-5 equals b1  b2; the average
treatment effect of community care relative to SCY equals b1  b3; and the average treatment effect of
MET/CBT-5 relative to SCY equals b2  b3.
Alternatively, we can pool data from three samples and estimate the ATE and population means
through a weighted linear regression of substance use frequency on indicator variables for two of the
three treatment groups. For each youth, the weight is the reciprocal of the propensity for the treatment
the youth received: The weights for youth in the community care sample equal the reciprocal of their
propensity scores for receiving community care; the weights for youth in the MET/CBT-5 sample equal
the reciprocal of their propensity scores for receiving MET/CBT-5; and the weights for youth in the SCY
sample equal the reciprocal of their propensity scores for receiving SCY. There is one weight variable,
and its value depends on each youth’s treatment status. If we include indicators for MET/CBT-5 and SCY,
then the coefficients on the indicator variables estimate the ATE of MET/CBT-5 relative to community
(2 1) and SCY relative to community (3 1). The estimate of the ATE of MET/CBT-5 relative to
SCY (2  3) is estimated by the difference of the coefficient for the indicators (the coefficient for the
MET/CBT-5 indicator minus the coefficient for the SCY indicator). When fitting the weighted regres-
sion, analysts should use a software package that accounts for weighting when estimating standard errors
such as the survey package in R or the SURVEYREG procedure in SAS or by specifying the weights
as analysis weights in STATA. The intercept is the estimate of the population mean for community, and
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Table IV. Treatment group means and pairwise ATEs and ATTs for substance frequency scale (100) before
and after weighting.
Community MET/CBT-5 SCY Difference (95% CI)
Unweighted
MET/CBT-5 vs. Community 11.4 6.7 4:7 (5:9, 3:5)
SCY vs. Community 11.4 7.7 3:8 (5:1, 2:4)
SCY vs. MET/CBT-5 6.7 7.7 1.0 (0.1, 1.8)
ATE weighted
MET/CBT-5 vs. Community 8.7 7.5 1:1 (3:0, 0.8)
SCY vs. Community 8.7 7.7 1:0 (3:0, 1.0)
SCY vs. MET/CBT-5 7.5 7.7 0.1 (0:8, 1.0)
ATT weighted to match community sample
Community vs. MET/CBT-5 11.5 8.6 2.9 (0.7, 5.2)
Community vs. SCY 11.5 8.8 2.8 (0.4, 5.1)
ATT weighted to match MET/CTB-5 sample
MET/CBT-5 vs. Community 8.5 6.8 1:7 (4:5, 1.1)
MET/CBT-5 vs. SCY 6.8 7.4 0:6 (1:5, 0.3)
ATT weighted to match SCY sample
SCY vs. Community 9.0 7.6 1:4 (3:5, 0.7)
SCY vs. MET/CBT-5 8.3 7.6 0:7 (1:8, 0.5)
the intercept plus the coefficient on the dummy indicator variables for each of the other treatments equal
the estimates of their population means.
Although estimating weighted means or fitting a weighted regression yields the same ATE estimates,
the regression approach has two advantages. First, it provides standard errors that can be used for con-
fidence intervals and hypothesis testing. Second, the regression approach naturally extends to doubly
robust estimation in the form of weighted regression that includes treatment indicators and covariates. In
this doubly robust approach, the treatment effects still can be estimated as the difference between pairs
of coefficients on the treatment group indicator variables. To obtain estimates of the population means
from a model that controls for covariates, we need to estimate the marginal means [48]. To do this, we
center the covariates at their unweighted overall sample means and then use the same combinations of
coefficients used in the model without covariates to estimate the various population means.¶
The Supporting information provides a sample code for estimating the pairwise ATE and population
means from models with and without additional covariates. Table IV shows the unweighted and weighted
regression results for the substance frequency scale at 12 months.
MET/CBT-5 versus Community. There are significant differences between the unweighted outcomes
for youth in both MET/CBT-5 and youth receiving the traditional community care, with youth receiv-
ing community care having more frequent drug use at the follow-up than the youth in the alternative
sample. However, as previously discussed, there are substantial pretreatment differences among groups,
so we should not interpret these differences as causal effects. When we weight the sample to control
for pretreatment differences and estimate the effects of treatment for the pooled sample, we find that the
estimated effects are much closer to zero than the raw differences and they are not statistically significant.
SCY versus Community. Again, there were significant differences between these two groups before
weighting, but the differences are much smaller and not significant when weighted.
SCY versus MET/CBT-5. The substance use frequency at follow-up for the youth from the MET/CBT-5
and SCY sample is very similar before weighting. Weighting has little effect on the difference between
these two groups because the two samples are very similar to the population on pretreatment variables
prior to weighting.
¶For dichotomous outcomes modeled by logistic regression, centering the covariates is not sufficient to yield marginal means,
and the methods of Graubard and Korn [48] must be used to estimate the population means.
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Pairwise ATTs
To estimate the ATT of MET/CBT-5 relative to community care for youth like those receiving commu-
nity care, we first subset the data to the MET/CBT-5 and community samples. We estimate the mean for
youth like those receiving community care had they received MET/CBT-5, 1;2, by the ATT weighted
mean of the MET/CBT-5 sample. The mean for youth like those receiving community care had they
received community care, 1;1, equals the unweighted mean for the community care sample. We can
again estimate the means and treatment effect using a weighted regression of substance use frequency on
the community indicator from the combined community and MET/CBT-5 samples. There is one weight
variable equal to one for youth in the community sample and equal to the ATT weight for youth in the
MET/CBT-5 sample. The coefficient on the community indicator equals the estimated ATT (1;11;2).
The means for the groups are estimated by the intercept (MET/CBT-5) and the sum of the intercept and
coefficient on the community indicator (community).
As with ATE, we can include covariates in the model for the outcome in our weighted regression to
obtain doubly robust estimates of the ATT. To obtain an estimates of 1;2, we center the covariates at
the mean of the community sample and use the intercept to estimate the counterfactual mean just as
we did in the model without covariates. We can use the unweighted mean for the community sample to
estimate 1;1.
We can repeat this approach using the SCY sample rather than the MET/CBT-5 sample to estimate
the relative effects of SCY and community care for youth like those who receive community care. We
can use a similar approach to estimate the ATTs for youth like those receiving MET/CBT-5 and SCY.
We suggest fitting two separate models, one for each pairwise ATT estimate. However, analysts can
pool datasets used to estimate the two sets of ATT weights, taking care not to duplicate the community
sample, and fit a single model with indicator variables for MET/CBT-5 and SCY. The coefficients on
the indicator variables for MET/CBT-5 and SCY estimate 1;2  1;1 and 1;3  1;3 and will equal
the estimates from the two separate models (except for the change in sign on the estimates) when no
covariates are included in the model. When the model includes covariates, fitting models separately for
each comparison and pooling may yield different treatment effect estimates because of differences in the
estimates of the coefficients on the covariates.
Table IV contains all the pairwise ATT estimates.||
Community. The results in Table IV indicate that among youth like those who are treated in the com-
munity setting, community treatment is less effective than MET/CBT-5 or SCY. The estimated effects
of community versus MET/CBT-5 or SCY for youth like those in the community sample are 0:029
(CI: 0:052 to 0:007) and 0:028 (CI: 0:051 to 0:004), respectively, after weighting and con-
trolling for unbalanced pretreatment variables for each comparison. Both estimates are statistically
significant. This could suggest that community treatment is poorly suited for the youth who typically
receive treatment in this setting. However, the groups are very different before weighting, a few sizeable
differences remain after weighting, and the overlap between the groups is weak. Hence, it is possi-
ble that the adjustments have not fully removed the confounding of the estimated causal effects by
pretreatment variables.
MET/CBT-5. Among youth who received MET/CBT-5, this treatment approach does not appear to
have beneficial effects relative to either of the other treatments. The estimate of the mean substance
use frequency for youth who received MET/CBT-5 had they instead received the community treatment
(i.e., the ATT weighted mean for the community sample) is 8.5, which is notably higher than the esti-
mated 6.8 for these youths outcomes following MET/CBT-5. However, the difference is imprecise and
not significant in large part because the effective community sample size is so low after ATT weighting of
the community youth to match the distribution of background variables of youth receiving MET/CBT-5.
The weighted mean of the outcomes from the SCY sample is very close to the mean for the MET/CBT-5
sample and not significant.
||Because of very small amounts of missing data on some of the pretreatment variables used for the modeling and for predicting
means, the mean for the community care for ATT with community as the target does not equal the unweighted mean for the
entire community sample and likewise for MET/CBT-5 and SCY.
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SCY. The results of the pairwise ATT analyses targeting youth in the SCY sample parallel those of ATT
for MET/CBT-5. There are notable differences between the weighted community mean and the SCY
mean, but the difference is not significant. The estimated effect of SCY relative to MET/CBT-5 on the
SCY sample is very small, again, indicating no differences in these two types of treatments.
5.3. Comment on the use of multinomial logistic regression to estimate weights
We also used multinomial logistic regression models to estimate propensity scores and weights for the
case study data to examine the balance it might provide as an alternative to using GBM. We estimated
the parametric model-based propensity score weights using the same set of pretreatment covariates that
were used in our GBM models; however, the multinomial model only includes main effects of the pre-
treatment covariates, which is a common practice. We did not tune the model further (e.g., by trying
various two-way or three-way interactions) because it was not clear which interactions would fix the
imbalances shown in the tables, particularly for the pairwise ATEs. Tables 1 and 2 in the Supporting
information highlight that in general, the multinomial logistic regression without cumbersome manual
model selection did not yield superior weights to our GBM approach in this case study. The ATE weights
that resulted from fitting the multinomial logistic model were very unstable and yielded very poor bal-
ance. Trimming the weights [19] or removing records with outlier weights improved balance, but it
remained inferior to the balance obtained using GBM. For ATT, the methods were more comparable,
but GBM continued to provide better balance. We note that 10% of the records in the data had missing
values on one or more covariates. GBM automatically adds indicators for missing values and includes
them in the model. Multinomial logistic regression requires a manual fix, such as imputation, creating
missing data indicators, or dropping incomplete records. When applying the parametric approach, we
dropped incomplete records for this illustrative analysis.
6. Discussion
This tutorial aimed to provide practical guidance for researchers on how to utilize propensity score
weights when estimating causal treatment effects of multiple treatment conditions. In estimating the
multiple treatment propensity score weights, a powerful machine learning method, GBM, was used to
obtain robust propensity score weights with better balance properties than a simple parametric model
(namely the multinomial logistic) did.
As shown in our example, the use of weighting can improve imbalances when interest lies in com-
paring more than two treatment programs, thereby allowing researchers to make more robust inferences
when estimating treatment effects. Before weighting, the community means differ significantly from the
other groups. After weighting, there were no differences between the ATE weighted MET/CBT-5 and
SCY samples and the population, and there were no pairwise ATE or ATT effects between these two
treatment programs. However, the weights were unable to completely remove differences among the
distributions of pretreatment variables between the community and other samples, and lingering imbal-
ances still existed after ATE weighting on five pretreatment covariates. In light of this, we utilized a
doubly robust modeling strategy to estimate the ATEs, which controlled for not only the propensity
score weights but also the five pretreatment variables for which imbalance still existed after weighting.
This method yielded no statistically significant pairwise ATE estimates. Similarly, there were remaining
imbalances with ATT weighting between the community sample and both of the other samples. Again,
we used a form of doubly robust estimation to estimate the pairwise ATT effects, which were significant
and suggested that community treatment is less effective than either of the alternatives for youth like
those who receive community care. However, the large differences among groups even after weighting
could result in residual confounding even with the doubly robust estimation, especially given the weak
overlap between the community and other samples.
The causal modeling of the case study has desirable properties. First, the causal estimands were clearly
defined prior to any analysis of the data. Then, transparent estimators of the estimands were defined and
estimated. The appropriateness of the samples for creating the counterfactuals necessary for causal effect
estimation was assessed via multiple graphical and tabular methods using only pretreatment variables.
The quality of the controls for confounding were also assessed graphically and through the balance
tables. Finally, the effects were estimated using methods that rely on linear models and weighting to
reduce the risk of confounding by observed pretreatment variables.
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When the groups are very dissimilar, as they were for the community sample and either of the
other groups in the example, weighting cannot always remove all differences among the groups. The
inability to achieve balance is particularly likely when the number of pretreatment variables is very
large relative to the overall sample size. But the tools presented here and automated in the twang
package in R make diagnosing such problems very easy. Also, as we saw in our example, when the
groups are disparate, weighting can be very inefficient because most of the weight is applied to very
few cases and most of the sample receives very little weight, making precise estimation of the causal
effects difficult.
Estimation of multiple causal effects is very similar to estimation of the effects with a single binary
treatment or a treatment and a control group. Our proposed method estimates multiple causal effects by
applying the binary tools multiple times. The balance metrics for ATE need to be adjusted to compare
estimates with the pooled sample rather than to the other treatment mean, but for ATT, the methods sim-
ply repeat the binary procedures for each pair of treatments. The powerful tools in the twang package
conduct these steps and are readily available for analysts to use.
The methods discussed in this tutorial do of course have their limitations. In particular, the meth-
ods only remove confounding by observed variables, at best. Condition 2, no unknown or unmeasured
confounders or exchangeability, must hold for unbiased estimation of the causal estimands. If there are
unmeasured variables that predict outcomes and differ among treatment groups, then the estimates can
be biased. This limitation, however, is not specific to the methods we present; indeed, all causal modeling
strategies that use observational study data must contend with this limitation in one way or another. Also
as discussed earlier, the methods cannot always balance the groups on observed pretreatment variables,
or doing so can yield very unstable weights and imprecise estimates. Again, this is not a limitation that is
specific to the methods we present. In fact, in our experience, using GBM to estimate propensity scores
can achieve balance when other methods cannot and with more stable weights.
Finally, methods for estimating the standard errors of the propensity scores estimated by GBM do
not exist. Consequently, principled methods for estimating the standard errors of the subsequent weights
also do not exist. In this paper, we approximate the standard errors of the ATE and ATT estimates using
robust (or so-called ‘sandwich’) standard errors. Robins et al. [12] suggested a similar approach for
marginal structural models with propensity scores estimated by parametric approaches. In limited simu-
lation experiments, robust standard errors for treatment effects estimated with GBM-based weights yield
conservative confidence intervals that cover the true value more than the nominal percent of time [18].
However, to our knowledge, theory does not exist that guarantees this to be true for GBM, and this is an
area for further statistical research.
Future research should more carefully explore various estimation methods for obtaining propensity
score weights when there are more than two treatment conditions in order to better understand under
which types of selection methods different estimation techniques prevail. From our personal experience,
GBM has outperformed the use of multinomial logistic regression when we have tried to balance more
than two treatment groups on pretreatment characteristics. Naturally, there will be applications for which
the selection mechanism will bring the performance of the two methods (GBM and multinomial logistic
regression) more inline. Table 2 in the Supporting information presents one such case where the two
methods have similar results (ATT for the community cases). However, even if multinomial logistic
regression can match the performance of GBM in some settings, GBM applied using the methods laid
out in this tutorial is a tool that belongs in every causal modeler’s tool box; it can yield better balance
with less variable weights and less manual user inputs than multinomial logistic regression, and it can
be implemented using available software.
Causal modeling is challenging. It requires estimating quantities that cannot be directly observed and
measured. Causal estimation of multiple treatment adds additional challenges because multiple compar-
isons are potentially of interest. Weighting provides a method for making these estimates, and the twang
package and the approach presented in this tutorial make weighting readily available and relatively easy
to implement.
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